Related Experiment Video
Updated: Jul 18, 2025
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.3K
Chronic Hepatitis B Infection: New Approaches towards Cure
Mojisola Ogunnaike1,2, Srijanee Das1,2, Samiksha S Raut1
1Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Biomolecules
|August 26, 2023
Summary
New long-acting treatments for chronic hepatitis B virus (HBV) infection show promise for improving patient adherence. These advancements include novel compounds and genome editing strategies targeting persistent viral DNA.
Area of Science:
- Hepatology and Virology
- Drug Development and Delivery Systems
Background:
- Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma.
- Current nucleotide/nucleoside antiviral therapies suppress HBV replication but require lifelong daily adherence, which can be challenging for patients.
Purpose of the Study:
- To review recent advances in long-acting formulations for HBV treatment and prevention.
- To summarize novel compounds targeting the HBV life cycle and curative strategies.
Main Methods:
- Review of current literature on long-acting antiviral formulations for HBV.
- Summary of emerging compounds and genome editing technologies for HBV cure.
Main Results:
- Long-acting formulations are being developed to potentially improve patient adherence to HBV therapy.
- New compounds targeting distinct steps in the HBV life cycle are under investigation.
- Curative strategies focus on eliminating covalently closed circular DNA and inactivating integrated viral DNA.
Conclusions:
- Long-acting antivirals and genome editing present promising avenues for improved HBV management and potential cure.
- These innovative approaches aim to overcome adherence challenges associated with current daily therapies.
